Even when a blocked artery is successfully reopened after stroke, roughly half of all patients never regain functional independence — a sobering reality that points to brain cell death as the true ceiling on recovery. This gap is now driving serious investigation into stem cell therapy as a post-thrombectomy adjunct, and the intra-arterial delivery route is emerging as a particularly practical candidate.
This review, published in Stroke (Hoboken), synthesizes the translational and early clinical literature on stem cell therapy for ischemic stroke, with a focused lens on intra-arterial administration. The logic is procedurally elegant: because mechanical thrombectomy already requires catheter access to the cerebral vasculature, clinicians could theoretically deliver stem cells through the same access point in the same session, targeting the ischemic penumbra directly. The authors examine the full pipeline — from animal models establishing proof-of-concept, to the formidable delivery challenges including cell viability, dosing windows, and the risk of microvascular occlusion from infused cells — and map these against the handful of early-phase human trials now underway.
For the broader research landscape, this review lands at an inflection point. Neuroprotection and neurorestoration have been the graveyard of countless stroke trials, with over a thousand failed interventions since the 1990s. Stem cell approaches differ mechanistically: rather than blocking a single molecular pathway, they aim to modulate inflammation, promote angiogenesis, and support endogenous repair networks simultaneously. The intra-arterial route offers concentration advantages over intravenous delivery but introduces its own risk profile, including embolic complications that prior trials have flagged. This is a review article — not a clinical trial — so it cannot establish efficacy or safety directly. Its value lies in consolidating a fragmented evidence base and setting the procedural and regulatory agenda for trials that could define the next decade of stroke rehabilitation. For health-conscious adults, the takeaway is that meaningful post-stroke recovery enhancement may eventually arrive not as a drug, but as a biological intervention delivered in the same procedure that saves lives today.